Aldeyra Therapeutics, Inc. (ALDX) Earnings History
Annual and quarterly earnings data from 2011 to 2024
Loading earnings history...
ALDX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ALDX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export ALDX earnings history in CSV or JSON format
Free sign-in required to download data
Aldeyra Therapeutics, Inc. (ALDX) Earnings Overview
As of May 8, 2026, Aldeyra Therapeutics, Inc. (ALDX) reported trailing twelve-month net income of -$43M, reflecting -46.9% year-over-year growth. The company earned $-0.72 per diluted share over the past four quarters.
Looking at the long-term picture, ALDX's historical earnings data spans multiple years. The company achieved its highest annual net income of $13M in fiscal 2013.
Aldeyra Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including OCUL (-$290M net income, -513.2% margin), KALA (-$36M net income), HALO ($317M net income, 22.7% margin), ALDX has comparable earnings metrics. Compare ALDX vs OCUL →
ALDX Earnings vs Peers
Earnings metrics vs comparable public companies
ALDX Historical Earnings Data (2011–2024)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$56M | -48.8% | -$60M | $-0.94 | - | - |
| 2023 | -$38M | +39.5% | -$43M | $-0.64 | - | - |
| 2022 | -$62M | -7.4% | -$63M | $-1.06 | - | - |
| 2021 | -$58M | -53.8% | -$56M | $-1.07 | - | - |
| 2020 | -$38M | +38.3% | -$35M | $-1.11 | - | - |
| 2019 | -$61M | -56.4% | -$63M | $-2.24 | - | - |
| 2018 | -$39M | -74.1% | -$40M | $-1.79 | - | - |
| 2017 | -$22M | -19.5% | -$22M | $-1.40 | - | - |
| 2016 | -$19M | -54.7% | -$19M | $-1.65 | - | - |
| 2015 | -$12M | -133.1% | -$12M | $-1.40 | - | - |
See ALDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALDX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALDX — Frequently Asked Questions
Quick answers to the most common questions about buying ALDX stock.
Is ALDX growing earnings?
ALDX EPS fell to $-0.72, with earnings declining -46.9%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-43M.
What are ALDX's profit margins?
Aldeyra Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ALDX's earnings?
ALDX earnings data spans 2011-2024. The declining earnings trend is -46.9% YoY. Historical data enables comparison across business cycles.